康复新液联合重组人粒细胞刺激因子注射液治疗放射性黏膜炎疗效分析  

Analysis of the therapeutic effect of Kangfuxin solution combined with recombinant human granulocyte stimulating factor injection in the treatment of radiation mucositis

作　　者：肖静 郑细优 万丽 蔡炜 XIAO Jing;ZHENG Xiyou;WAN Li;CAI Wei(Pharmacy Department of General Hospital of Pingxiang Mining Group Co.,Ltd.Jiangxi 337000,China)

机构地区：[1]江西省萍乡矿业集团有限责任公司总医院药剂科,江西萍乡337000

出　　处：《上海医药》2020年第6期34-36,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨康复新液联合重组人粒细胞刺激因子注射液治疗放射性黏膜炎的疗效。方法:收集2017年10月—2018年12月行放射治疗的头颈部恶性肿瘤患者62例,分为观察组和对照组各31例,两组患者放射治疗开始后即给予口腔护理。对照组予以地塞米松5 mg+庆大霉素8万U+利多卡因400 mg+0.9%生理盐水80 ml混合,每次20 ml,分别于三餐后和睡前含漱。观察组予以康复新液含漱,每次10~15 ml,每日3次;重组人粒细胞刺激因子注射液300mg+0.9%生理盐水80 ml混合,每次含漱20 ml,每日3次。采用疼痛数字分级法(NRS)评估患者放射治疗期间口咽评分变化情况及治疗结束时放射性黏膜炎发生情况。结果:观察组放疗后2、3、5周及放疗结束时口咽疼痛NRS评分均低于对照组(P<0.05)。观察组放射治疗结束时1级放射性黏膜炎所占比例高于对照组,3级、4级放射性黏膜炎所占比例低于对照组,P<0.05。结论:康复新液联合重组人粒细胞刺激因子注射液可明显减轻放射治疗患者口咽疼痛和放射性黏膜炎严重度,值得临床推荐。Objective:To explore the therapeutic effect of Kangfuxin solution combined with recombinant human granulocyte stimulating factor injection in the treatment of radiation mucositis.Methods:Sixty-two patients with head and neck cancer who received radiotherapy from October 2017 to December 2018 were collected,and according to the principle of random control divided into an observation group and a control group with 31 cases in each group.The control group was given dexamethasone 5 mg+gentamicin 80000 U+lidocaine 400 mg+0.9%physiological saline 80 ml,and gargled 20 ml each time after three meals and before bedtime,respectively and the observation group was given Kangfuxin solution gargle,10-15 ml each time,3 times a day;recombinant human granulocyte stimulating factor injection 300μg+0.9%physiological saline 80 ml were mixed and gargled 20 ml each time,three times a day.The pain digital grading method(NRS)was used to evaluate the changes of oropharyngeal scores during radiation therapy and the occurrence of radiation mucositis at the end of treatment.Results:The NRS score of oropharyngeal pain in the observation group was lower than that in the control group at 2,3,and 5 weeks and the end of radiotherapy(P 0.05).The proportion of grade 1 radiation mucositis in the observation group was higher than that in the control group at the end of radiotherapy,and the proportions of grade 3 and 4 radiation mucositis in the observation group were lower than those in the control group(P<0.05).Conclusion:Kangfuxin solution combined with recombinant human granulocyte stimulating factor injection can significantly reduce the oropharyngeal pain and the severity of radiation mucositis in patients undergoing radiotherapy,which is worthy of clinical recommendation.

关 键 词：放射性黏膜炎 康复新液 重组人粒细胞刺激因子注射液 口咽疼痛 

分 类 号：R818.8[医药卫生—放射医学]